Annate Bitherapeutics CEO Eric DeJesus was named the winner of the 2025 UGA Quick Pitch Event, recognizing his entrepreneurial vision and the company’s innovative cancer therapeutic platform. Read More ›
Annate Bitherapeutics has been added to the University of Georgia’s InPart technology portal, expanding opportunities for collaboration and industry engagement. Read More ›
Annate Bitherapeutics was named the pitch competition winner at the 2025 Georgia Life Sciences Summit Startup Showcase, earning one-on-one mentorship with the BioTech Execs Network. Read More ›
Annate Bitherapeutics has been selected for the Startup Showcase at the 2025 Georgia Life Sciences Summit, joining a prestigious lineup of Georgia-based innovators. Read More ›
The ARCS Foundation has recognized Eric DeJesus, PhD, both in a feature article and through his June 2025 ARCS Forward talk on reducing the impact of cancer. Read More ›
Join ARCS Scholar Alum Eric DeJesus, PhD (Founder & CEO, Annate Bitherapeutics) on June 10 as he discusses innovative cancer-targeting immunotherapies. Read More ›
The University of Georgia highlighted Annate Bitherapeutics at the inaugural Southeastern Venture Showcase in Nashville, recognizing the company among a select group of early-stage ventures advancing research-driven innovation. Read More ›
The Southeast Venture Showcase is a transformational event that empowers research universities and federal laboratories across the Southeast to showcase their most promising technology ventures for the nation’s venture community. Read More ›
In recognition of the significant strides made in Phase Ia and Phase Ib, the Georgia Research Alliance has awarded a $25,000 Phase Ic grant to Annate Bitherapeutics and the Hajduk Lab at the University of Georgia. This grant will specifically support the advancement of proof-of-concept animal studies, a critical step in the development of their innovative therapeutic against Multiple Myeloma. Read More ›
The Winship Cancer Institute of Emory University together with the University of Georgia Cancer Center are delighted to unveil the latest recipients of the Winship-UGA Collaborative Pilot Grant. This prestigious, peer-reviewed award fosters collaboration between faculty members from both institutions, driving forward innovative research in the fight against cancer. This year's grant is dedicated to advancing research in ApoL1 targeted therapies, with a focus on combating pancreatic cancer. Read More ›
Over 65 ARCS members and guests gathered at the downtown Capital City Club on January 17, 2024, for one of the most exciting General Membership Meetings in recent memory. Former ARCS Scholar Dr. Eric DeJesus spoke about the formation of his new company, Annate BiTherapeutics, Inc. which is based on the research he began as an ARCS scholar at the University of Georgia. Read More ›
In a significant endorsement of innovative cancer research, the Georgia Research Alliance (GRA) has awarded an additional $25,000 in funding to Annate Bitherapeutics, following a triumphant completion of a Phase Ia project. This investment will bolster the collaborative efforts with the Hajduk Lab at the University of Georgia to advance the development of their promising lead therapeutic for combating Multiple Myeloma. Read More ›
The Georgia Research Alliance demonstrates its unwavering support for medical innovation by awarding a $25,000 grant to Annate Bitherapeutics in partnership with the Hajduk Lab at the University of Georgia. This strategic funding marks the initiation of Phase Ia in the development of a cutting-edge therapeutic targeting Multiple Myeloma. Read More ›
